Posts Tagged ‘African sleeping sickness’

Doctors without Borders on The Hill

July 21st, 2010

By: Alanna Shaikh

Medecins sans Frontieres (Doctors without Borders) testified before the US congress today on Neglected Tropical Diseases. The testimony, from Suerie Moon on the U.S. Board of Directors of MSF, was a valuable reminder of why we continue to fight the NTDs, and introduced some of MSF’s core principles in global health. It’s an interesting speech.

She began by talking about NTDs. Her focus was on Chagas diseases, which is a major MSF focus, but the content applies to all the NTDS. First, she pointed out that the US presidential neglected tropical disease initiative only covered 5 out of the 14 Neglected Tropical Diseases. Chagas, as MSF was quick to point out, was not included. Neither were kala azar (aka Visceral leishmaniasis) or Trypanosomiasis (African sleeping sickness).

» Read more: Doctors without Borders on The Hill

Good News, Bad News

July 1st, 2010

By: Alanna Shaikh

Two of the links that we just posted are concrete reminders that we understand the Neglected Tropical Diseases. We know what causes them and we know how to control them. Their path is predictable. What we need is the will to keep on fighting them.

Case A: Human African Trypanosomiasis, A Success Story

The WHO reported that Human African Trypanosomiasis is at a 50-year low. The number of new cases reported has now dropped below 10,000. The WHO attributes the success to “Strengthened control and surveillance efforts by national sleeping sickness programmes in endemic countries over the past 10 years…”

In other words, we knew what to do to fight the disease, and then we did it. Dr Hiroki Nakatani, WHO’s Assistant Director-General for HIV/AIDS, TB, Malaria and Neglected Tropical Diseases, puts it a bit more elegantly, “It is a brilliant demonstration of what can be done with determined and clear day-to-day control efforts, particularly in the absence of new tools.”

In this case, the control effort included better surveillance and case reporting (which negated my fear that we were seeing fewer reported cases because reporting was getting worse), consistent donor support, drug donations, and a partnership with a pharmaceutical company. It’s clear we could apply those methods to more than just Trypanosomiasis. This is the magic formula for fighting many diseases, not just NTDs.

Case B: Dengue, A Frightening Portent of the Global Future

This one is not good news: Dengue fever has returned to the continental United States. This is not a case of people being infected with Dengue while traveling and then entering the US. This is actual infection within the United States. We haven’t seen that in 65 years, and it’s back.

It’s not a surprise. We knew this was going to happen. Here, the New York Times says it better than I could “The upsurge is not unexpected. Experts say more than half the world’s population will be at risk by 2085 because of greater urbanization, global travel and climate change.” (they go on to make a really stupid comment about DDT, which we shall ignore.)  There is a reason that I wanted to rename NTDs to “Diseases that might be in hot countries right now, but with global warming they’ll soon be affecting you right there in Minneapolis.”

If we don’t put more work into fighting NTDs where they are endemic now, there are going to be endemic in a lot more places in the future. I wrote about this last week with regard to Chagas.

Maybe we can try to see this as a positive. Now that NTDs are starting to affect wealthy countries, we may see a lot more research and development of new drugs. There are no drugs for Dengue right now, but Sanofi Pasteur is working on a vaccine. Pairing a solid (solid like as much as a billion dollars solid) profit incentive with a humanitarian motive might be exactly what we need to get it to market.

Alanna Shaikh is an expert in health consulting, writing about global health for UN Dispatch and about international relief and development at Blood & Milk. She also serves as a frequently contributing blogger to ‘End the Neglect.”

Reading List 4/19/2010

April 19th, 2010

Happy Monday, everybody. Today we’re reading about the possibility of a new treatment for sleeping sickness, watching a video report about Jimmy Carter and the fight against Guinea worm, and reading Bono’s op-ed about aid in Africa.

Sleeping sickness: could a new drug be in prospect?, Paul Chinnock, TropIKA.net
Eradicating a Global Scourge, Fred De Sam Lazaro, PBS
Africa Reboots, Bono, New York Times

Moving Towards the Future of NTD Treatment

April 9th, 2010

The bit of the sandfly transmits leishmaniasis to humans. Picture credit James Gathany.

The bite of the sandfly transmits leishmaniasis to humans. Picture credit James Gathany.

Lack of innovation has long been one of the most lamented problems with neglected tropical disease (NTD) treatment. Most drugs for treating NTDs, though effective, were developed decades ago. The longer a treatment gets used, the greater risk of the disease becoming resistant towards it. A non-NTD example of the risks of drug resistance would be drug-resistant tuberculosis . While there still remains an innovation gap for NTDs, there has been a building effort to develop new, innovative treatments for NTDs. And in one of life’s odd coincidences, the celebration of World Health Day this past week capped a week of breakthroughs which could lead to new, effective treatments for diseases in dire need of them.

Human African trypanosomiasis, better known as African sleeping sickness, is a parasitic disease that affects an estimated 50,000-70,000 people in sub-Saharan Africa and is 100% lethal if untreated . Unfortunately, the two treatments for sleeping sickness are antiquated and insufficient. One treatment requires prolonged hospitalization with limited effectiveness, and the other treatment is based off of arsenic and kills 20% of those treated. However, there may soon be a new treatment for sleeping sickness thanks to a breakthrough by scientists at the Drug Discovery for Tropical Diseases program at Dundee University in England . They’ve successfully isolated a compound which attacks an enzyme necessary for the parasite to survive. Test treatments in lab mice caused rapid and complete elimination of the disease. With human trials beginning in as soon as 18 months, we may be just a few years away from a safe and effective treatment for this horrific disease.

But if such a treatment is a few years away, what can be done in the meanwhile? That’s answered by another breakthrough in the fight against sleeping sickness. Sleeping sickness is spread by the tsetse fly, so trapping the fly would do a great deal too slow to stop the spread of the disease. This past week, research from Burkina Faso and Ivory Coast were able to identify the chemicals which most effectively attract the tsetse fly. Test traps using these chemicals resulted in an up to five-fold increase in the number of flies trapped. This technology will be field tested in the near future and, if successful, would provide an effective, and relatively cheap, means of fighting sleeping sickness. These two breakthroughs combined make the future for sleeping sickness treatment look much brighter than just a week ago.

Leishmaniasis, a lethal parasitic disease transmitted by sandflies, also saw a promising breakthrough. A survey to create a genetic barcode of sandflies in Panama revealed an interesting fact: both species of sandfly which carry the Leishmania parasite also carry the Wolbachia parasite. The importance of this is that Wolbachia affects the reproductive ability of the flies and could be an effective biological control for sandflies.

Together, these three breakthroughs are a promising sign for NTD treatment. Not only do they promise effective ways of combating two horrific NTDs, but they also show that the ongoing push for innovation of NTD treatment is starting to pay dividends and bringing us closer to a future free of NTDs.

Reading List 4/1/2010

April 1st, 2010

Happy April everybody! Today we’ve got a bunch of NTD related news, including some ongoing advocacy work and a possible breakthrough against African sleeping sickness (no foolin’).

Scientists open way for new sleeping sickness drug, Kate Kelland, Reuters
Members of Congress Urge Spending Boost for Neglected Diseases, Joe DeCapua, Voice of America
HEALTH: Seeking Funds to Fight Neglected Diseases, Fabiana Frayssinet, IPS
Vaccines, The Modern “Olive Branch”?, Josh Witten, Scientific Blogging
Killer diseases of Africa’s poor, Pamela Olet, Daily Nation
Blindness Prevention Initiative, AmeriCares, Reuters AlertNet

Reading List 3/16/2010

March 16th, 2010

Today we’re reading about a promising new treatment for African sleeping sickness, the response to a new outbreak of schistosomiasis in Zimbabwe, and the UK upping its giving to the GAVI Alliance.

WHO approves trial drug for sleeping sickness, Frank Mugabi, The New Vision

Following Outbreak of Bilharzia in Zimbabwe, Officials Step Up Public Education, Brenda Moyo, Voice of America

UK doubles funding to GAVI Alliance, GAVI

Night 8: The “Other” NTDs

December 19th, 2009

Tonight we’ll wrap up our Hannukah and NTDs series with a focus on the remaining NTDs as defined by the WHO: buruli ulcer, dengue fever, guinea worm, African sleeping sickness, leishmaniasis, and leprosy.  At the Global Network, we are commonly asked “why do you only focus on seven NTDs?”  The seven NTDs we’ve detailed over the last seven nights are the most common NTDs, representing approximately 90% of the total disease burden.  We also focus on them, however, because they are generally referred to as “tool-ready”–that is to say, we have medications that are safe, affordable, and available to treat the seven most common.

Which brings us to the “other” NTDs that also cause significant suffering among the poorest of the world’s communities. Like the most common ones, these NTDs promote the continuation of poverty in developing communities by impairing physical and intellectual growth and decreasing worker productivity.  But unlike the others, they are either missing treatment/control tools altogether or the tools are difficult to access or afford.

Many groups are working to change this landscape.  Analysis from Drugs for Neglected Diseases initiative (DNDi) clarifies:

For the “most neglected” diseases, patients are so poor that they have virtually no purchasing power and cannot spark market interest in drug R&D among pharmaceutical companies. Recently, the field of R&D for neglected diseases has seen the emergence of several new organisations, new donors, new financial mechanisms, and a new political environment. However, although the global R&D landscape has improved for neglected diseases since 2003, the dire needs of the most neglected victims who carry on suffering in the developing world are still largely unmet. A recent study by G-Finder revealed that less than 5 percent of worldwide R&D funding for neglected diseases has been directed towards the most neglected diseases.

To read more about these NTDs, visist our website.